Search Images Maps Play YouTube Gmail Drive Calendar More »
Settings | Sign in


GlaxoSmithKline PLC (GSK) Upgraded to "Hold" by Zacks Investment Research

BBNS - ‎20 hours ago‎
GlaxoSmithKline PLC logo GlaxoSmithKline PLC (NYSE:GSK) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Monday.
See realtime coverage

GlaxoSmithKline inks deals with Publicis Groupe, WPP and IPG as it consolidates global ad duties into 9 shops

The Drum - ‎Jul 19, 2016‎
Following the announcement that it was putting every one of its brands locally and globally under review, GlaxoSmithKline (GSK) has announced that it will consolidate its global estimated $1bn roster to nine agencies, inking major deals with Publicis ...
See realtime coverage

GlaxoSmithKline: a prescription for success

News.Markets - ‎Jul 25, 2016‎
FTSE 100-listed healthcare giant GlaxoSmithKline (LON:GSK) reports its second-quarter earnings on July 27 with a raft of analysts upgrading the company and hiking their target prices ever higher with a combination of a strong product line, positive ...

Business on the Move: Account wins and reviews from GlaxoSmithKline, Spotify, Carling, UK Athletics and more

The Drum - ‎Jul 22, 2016‎
Welcome to The Drum's Account Roundup. To help you stay up to date, each Friday we bring you a summary of the latest account wins and reviews taking place across the industry both globally and locally.

Analysts Tips to Monitor: Merck & Company, Inc. (NYSE:MRK) , GlaxoSmithKline PLC (NYSE:GSK)

Street Updates - ‎Jul 25, 2016‎
Merck & Company, Inc. (NYSE:MRK) accumulated +0.05%, closing at $58.82 after floating between $58.55 and $59.08. The company has market capitalization of $162.82B.

GlaxoSmithKline (LON:GSK) Broker Price Targets

Fiscal Standard - ‎8 hours ago‎
Recently stock market research analysts have changed their consensus ratings and price targets on shares of GlaxoSmithKline (LON:GSK). The latest broker reports which are currently outstanding on Tuesday 26th of July state 8 analysts have a rating of ...

GlaxoSmithKline's Sideways Dance May Pay Off in the Long Run - ‎Jul 22, 2016‎
During the first quarter, GlaxoSmithKline (NYSE:GSK)'s pharma division brought in 3.58 billion British pounds, down 1%; vaccines grew 23% to reach 883 million; and consumer health care grew 26% to 1.76 billion.

Apple Scores GlaxoSmithKline Study in Key Test of Health Apps

Bloomberg - ‎Jul 15, 2016‎
GlaxoSmithKline Plc has started a rheumatoid arthritis study using Apple Inc.'s ResearchKit, marking the first time a drugmaker has used the health system for the iPhone to conduct clinical research.
See realtime coverage

GlaxoSmithKline Segments That Drive Company's Rising Revenues

Market Realist - ‎Jul 22, 2016‎
Analysts expect a growth of ~7.8% in GlaxoSmithKline's (GSK) 2Q16 revenues, to 6.4 billion British pounds. This follows strong product launches and improvements in the supply chain.

Investor Watch: Earnings and Street Rating Review for GlaxoSmithKline PLC (NYSE:GSK)

Engelwood Daily - ‎1 hour ago‎
Investors and analysts will be waiting to see if the company hits or misses earnings projections after the next earnings report. GlaxoSmithKline PLC (NYSE:GSK) is scheduled to next post quarterly results on or around 2016-07-27. The company most ...

Will GlaxoSmithKline plc and AstraZeneca plc continue to be Brexit winners?

Motley Fool UK - ‎Jul 18, 2016‎
The list of FTSE 100 Brexit winners is far longer than anybody could have imagined, and pharmaceutical giants AstraZeneca (LSE: AZN) and GlaxoSmithKline (LSE: GSK) figure highly. As the nation went to bed on 23 June anticipating a Remain victory, ...

Key Stocks of the Day: GlaxoSmithKline plc (NYSE:GSK)

The News Journal - ‎16 hours ago‎
As it reflects the theoretical cost of buying the company's shares, the market cap of GlaxoSmithKline plc (NYSE:GSK) is currently rolling at 105411.61, making it one of the key stocks in today's market.

Stock Seeing a Downward Gap Before the Open: GlaxoSmithKline plc (NYSE:GSK)

TGP - ‎Jul 25, 2016‎
Shares of GlaxoSmithKline plc NYSE:GSK gapped down -0.11% between sessions as the shares stand at $43.88 before the open. A gap is a space between prices that occurs when the price of a stock makes a move down or up when there is no trading ...

Stock Seeing Accelerated Growth, But Can it Continue: GlaxoSmithKline plc (NYSE:GSK)

TGP - ‎18 hours ago‎
Shares of GlaxoSmithKline plc (NYSE:GSK) have been experiencing an accelerated earnings and sales growth over the past 5 years.

BRIEF-GlaxoSmithKline ships 2016-17 seasonal influenza vaccines for US market

Reuters - ‎Jul 20, 2016‎
July 20 GlaxoSmithKline Plc : * GSK ships 2016-17 seasonal influenza vaccines for US market. * Expects to supply up to 40 million doses across both vaccines for US market in 2016-17 season Source text for Eikon: Further company coverage: (Bengaluru ...

GlaxoSmithKline PLC (NYSE:GSK) Has Been Assigned An ABR Of 2.2

Markets Daily - ‎16 hours ago‎
GlaxoSmithKline PLC (NYSE:GSK) stock has bullish outlook. Based on the survey data released by the Zacks as of 2016-07-24, the stock of GlaxoSmithKline PLC (NYSE:GSK) has been assigned an ABR of 2.2 rating. The ABR of one is a signal to go ahead ...

GlaxoSmithKline PLC (NYSE:GSK) Updated Price Targets

FTSE News - ‎Jul 22, 2016‎
07/19/2016 - GlaxoSmithKline PLC had its “hold” rating reiterated by analysts at Shore Capital Stockbrokers. 07/14/2016 - GlaxoSmithKline PLC was upgraded to “buy” by analysts at Jefferies. 07/01/2016 - GlaxoSmithKline PLC was upgraded to “buy” by ...

FDA sends stern warning to Glaxo over contamination at a penicillin plant

STAT - ‎Jul 20, 2016‎
GlaxoSmithKline is recalling a “small” number of batches of its Bactroban antibiotic following a harsh rebuke from US regulators about contamination at a key plant.

Quick Look Sell-side Earnings Watch: MetLife, Inc. (NYSE:MET), GlaxoSmithKline PLC (NYSE:GSK), CSI Compressco ...

Engelwood Daily - ‎17 hours ago‎
Analysts are projecting that GlaxoSmithKline PLC (NYSE:GSK) will report EPS of $0.54 when they next file their quarterly earnings.